The EMA has recommended refusing marketing authorization for donanemab, a monoclonal antibody against amyloid beta, in the treatment of Alzheimer's disease.

Healthy rivers and access to clean water are fundamental human rights that connect us all. The International Day of Action for Rivers is a time to come together in solidarity with rivers and the ...

Lilly is seeking approval for donanemab in early-stage Alzheimer's, and is hoping to get a speedy FDA green light on the back of amyloid clearance data as a surrogate marker for clinical efficacy ...

EU countries have agreed on a market correction mechanism which will limit episodes of extraordinarily high gas prices in the EU and thus reduce the impact of price hikes on citizens and the economy.

But some experts say the side effects of the drug called donanemab may outweigh its benefits. It was given the green light by UK drug regulators, the Medicines and Healthcare Products Regulatory ...

Action films are one of the most streamed genres on OTT, period. While there is no dearth of such films across the platforms, their popularity has led the platforms to produce their own action films ...

The National Institute for Health and Care Excellence (NICE) has decided to reconsult on draft guidance for Alzheimer’s treatments donanemab and lecanemab, six months after initially rejecting the ...

For research papers The BMJ has fully open peer review. This means that accepted research papers published from early 2015 onwards usually have their prepublication history posted alongside them on ...

There’s a reason that the most successful genre on the home market has been the same for over a generation now: People love action movies. They allow us to escape reality and enter a world where ...

We respond to the disappointing decision NICE has made to not recommend donanemab and lecanemab on the NHS. On Thursday, 6 March, NICE published further draft guidance for public consultation that ...

When I think of a tough little camera built to capture action, GoPro naturally comes to mind, doesn't it? It's so ingrained that I was out testing a competing brand and my then 7-year-old son called ...